Furthermore, there is in vivo evidence of the oncogenic role of EGFR vIII in a NSCLC murine model and of the efficacy of an EGFR inhibitor, HKI-272, in this model [91]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.